Depression as a Mind-Body Disorder in Minority Populations: Special Challenges in Diagnosis and Treatment
neuroscienceCME Webcast
Premiere Date: Monday, September 22, 2008This activity is a companion to a monograph titled Depression as a Mind-Body Disorder in Minority Populations: Special Challenges in Diagnosis and Treatment.
If you would like more information, please click here.
This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, September 22, 2009
Note: Credit Is No Longer Available
 | Rakesh Jain, MD, MPH Clinical Professor, Department of Psychiatry Texas Tech Health Sciences Center School of Medicine – Permian Basin Midland, TX |
 | Rahn Kennedy Bailey, MD, FAPA Chairman of Psychiatry Executive Director of Elam MHC Meharry Medical School Vice Speaker, House of Delegates National Medical Association Deputy Representative, Black Caucus American Psychiatry Association Nashville, TN |
 | Vladimir Maletic, MD Associate Clinical Professor of Neuropsychiatry and Behavioral Science University of South Carolina School of Medicine Columbia, SC Consulting Associate, Division of Child and Adolescent Psychiatry Department of Psychiatry Duke University Durham, NC |
 | Madhukar H. Trivedi, MD Professor of Psychiatry Betty Jo Hay Distinguished Chair in Mental Health University of Texas Southwestern Medical Center Dallas, TX |
Despite the availability of clinical guidelines for the identification and treatment of patients with major depression,
studies consistently report that patients with depression are not diagnosed or treated as often as necessary. This
is especially true when it comes to patients of racial or ethnic minority.(1) However, the effectiveness of treating
depression in minority patients has been demonstrated.(2-7) Therefore there is a critical need to educate clinicians to
screen, diagnose, and treat minority patients with depression within the context of cultural sensitivity and to provide
clinicians with the skills to overcome any cultural issues that may impede diagnosis and successful treatment of
minority patients with depression. Healthcare providers caring for minority populations need to actively engage
patients in their treatment and regularly follow-up with these patients to ensure compliance with therapy and the
best outcome for the patients.
- Williams DR, et al. Arch Gen Psychiatry 2007;64:305-315.
- Hong Ng C, et al. Int Clin Psychopharmacol 2006;21:87-92.
- Pinto C, et al. J Indian Med Assoc 2007;105:364-368.
- Wu YS, et al. J Clin Pharm Ther 2007;32:353-363.
- Lee P, et al. Psychiatry Clin Neurosci 2007;61:295-307.
- Lewis-Fernandez R, et al. J Clin Psychiatry 2006;67;1379-1390.
- Bailey RK, et al. J Natl Med Assoc 2006;98:437-447.
To enable healthcare providers to gain insight into the specific needs of minorities when they are treated for depression, including such items as diagnosis, screening, compliance, and stigma.
At the end of this CE activity, participants should be able to:
- Identify manifestations of depression in minorities.
- Apply culturally sensitive approaches to involve minority patients in the diagnosis and treatment of depression.
- Create goal-directed therapy plans to treat depression in minority patients.
This continuing education activity is jointly sponsored by Quadrant Medical Education and CME Outfitters, LLC. The joint sponsors gratefully acknowledge an educational grant from Eli Lilly and Company and Wyeth Pharmaceuticals in support of this CE activity.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in mental health.
CME Credit (Physicians):
This activity has been planned and implemented in
accordance with the Essential Areas and Policies of the Accreditation Council for
Continuing Medical Education through the joint sponsorship of CME Outfitters, LLC,
and Quadrant Medical Education. CME Outfitters, LLC, is accredited by the ACCME to
provide continuing medical education for physicians.
CME Outfitters, LLC, designates this educational activity for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim
credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved provider of continuing
nursing education by the New York State Nurses Association, an accredited approver
by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned code 6WASUP-PRV-0640. 1.0 contact hours will be awarded
upon successful completion. This activity is co-provided with Quadrant Medical
Education.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological
Association to sponsor continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association
of Social Workers (provider #886407722) for 1 continuing education contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-08-017-H04-P
Credit request forms/activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).
This CE activity can be used toward mandatory Cultural Competence CE requirements in states where applicable.
Rahn Kennedy Bailey, MD, FAPA
Dr. Bailey is a dual board-certified forensic psychiatrist. He completed his general psychiatric training at the University of Texas
Medical School in June 1994. Thereafter, Dr. Bailey completed his forensic psychiatric fellowship at Yale University in June 1995. He
became board certified in general psychiatry in March 1998. In April 1999, he achieved board certification in Forensic Psychiatry.
Dr. Bailey recently held positions as an Associate Professor at University of Alabama-Birmingham and Past Director of Bryce
Hospital in Alabama. Dr. Bailey currently serves as Chairman of the Department of Psychiatry and Behavioral Sciences at the
School of Medicine of Meharry Medical College in Nashville, TN.
Dr. Bailey served as the Secretary to the House of Delegates of the NMA in 2006-2007. He was elected as the Vice Speaker in
August, 2007 and currently serves the Association in this role. He is a member of the Administrative Council of the American
Academy of Psychiatry and Law (AAPL). Dr. Bailey is a staff physician at Clear Lake Regional Hospital. He has served as a Principal
Investigator for several clinical research studies. He is a national forensic expert, who has testified and participated in both civil,
racial discrimination, and criminal cases both locally and nationally. Of particular note, he is a psychiatrist for the State of Texas
which involves evaluating Sexually Violent Predator (SVP). He evaluates and provides treatment assessments for the United States
and Texas Rehabilitation Commission. Additionally, he is an expert for the Federal Social Security Office of Disability Hearings and
Appeals. He has testified in five states (Texas, Louisiana, Kansas, Indiana, and Connecticut). He has written and lectured on various
forensic topics including Confidentiality, Insanity Defense, and Ethnic Differences in Psychopharmacology, Competency and
Medical Student Education. In addition, he has written various articles on Post Traumatic Stress Disorder, Sexual Offenders, Ethics
in Forensic Practice, Juvenile Crime, Capital Punishment, Atypical Antipsychotic Treatment and Efficacy, Cocaine Dependence and
Clinical Treatment, and Stalking. Dr. Bailey has been featured live on MSNBC Television, as well as on Cable Network News (CNN),
and on local TV/Radio discussing Psychiatric Treatment, the Insanity Defense and Violent Criminal Behaviors. Dr. Bailey is currently
the host of “Good Psychiatry is Good Medicine”, a weekly radio program on Voice America Internet Radio.
Vladimir Maletic, MD
Dr. Maletic is Associate Clinical Professor of Neuropsychiatry and Behavioral Science at the University of South Carolina School
of Medicine in Columbia, and Consulting Associate in the Division of Child and Adolescent Psychiatry in the Department of
Psychiatry at Duke University in Durham, North Carolina. Dr. Maletic received his MD in 1981 and his MS in Neurosciences in 1985,
both at the University of Belgrade in Yugoslavia. He went on to serve a residency in Psychiatry at the Medical College of Wisconsin
in Milwaukee, followed by a residency in Child Psychiatry at Duke University.
Dr. Maletic is a member of several professional organizations, including the Southern Psychiatric Association. In addition, he has
published numerous articles and has participated in various national and international meetings and congresses. His special areas
of interest include neurobiology of mood disorders, anxiety disorders, ADHD and regulation of sleep and wakefulness. Dr. Maletic
is board-certified in Psychiatry and Neurology.
Madhukar H. Trivedi, MD
Dr. Trivedi is currently a Professor and Chief of the Division of Mood Disorders, Department of Psychiatry, University of Texas Southwestern
Medical Center at Dallas. He holds the Betty Jo Hay Distinguished Chair in Mental Health and the Lydia Bryant Test Professorship
in Psychiatric Research. Dr. Trivedi is an established efficacy and effectiveness researcher in the treatment of depression.
Dr. Trivedi has been a principal investigator in multiple clinical trials funded through NIMH and the Texas Department of Mental
Health. He has been involved with evidence-based depression guideline development since 1990, when he joined the Depression
Guideline Panel of the AHCPR. Dr. Trivedi has been the Director of the Depression Algorithm for TMAP since its inception. Dr.
Trivedi has served as the chair of the Depression Work Group of the International Psychopharmacology Algorithm Project and as
the scientific content expert for the San Antonio Cochrane Center’s evidence-based, AHCPR-funded efforts to update the Depression
Guidelines. Dr. Trivedi spearheaded the rollout of best practices for the treatment of MDD in various MHMR centers across the
State of Texas. Dr. Trivedi is also studying the effectiveness of treatments of Depression in Primary Care.
Dr. Trivedi was also the co-principal investigator of the NIMH-funded project entitled “Sequenced Treatment Alternatives to Relieve
Depression” (STAR*D). Dr. Trivedi is currently the co-principal investigator of the Depression Trials Network Combining Medication
to Enhance Depression Outcomes (COMED) trial, which focuses on the use of specific antidepressant combinations to increase
remission rates by treating a broader spectrum of depressed patients and by capitalizing on additive pharmacological effects. Dr.
Trivedi is also principal investigator of three current NIMH grants entitled “CBASP Augmentation for Treatment of Chronic Depression
(REVAMP),” “TReatment with Exercise Augmentation for Depression (TREAD),” and “Computerized Decision Support System
for Depression (CDSS-D).”
Dr. Trivedi has mentored multiple psychopharmacology postdoctoral fellows and research track residents over the past many
years in the Mood and Anxiety Disorders.
Dr. Trivedi has received numerous awards including the Gerald L. Klerman award from the National Depressive and Manic-Depressive
Association Scientific Advisory Board-NDMDA and the Psychiatric Excellence Award from the Texas Society of Psychiatric
Physicians-TSPP.
Dr. Trivedi is or has been a member of several institutional review groups of the NIMH. Dr. Trivedi has published over 275 articles
and chapters related to the Diagnosis and Treatment of Mood Disorders.
Rakesh Jain, MD, MPH, Moderator
Dr. Jain is Director of Psychiatric Drug Research for the R/D Clinical,Research Center at Lake Jackson, Texas. Dr. Jain attended
medical school at the University of Calcutta in India. He then attended graduate school at the University of Texas School of Public
Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research
thesis focused on alcohol abuse issues. He graduated from the School of Public Health in 1987 with a Masters of Public Health
(MPH) degree. After graduate school, Dr. Jain completed a postdoctoral fellowship in Research Psychiatry with the Gerontology
Center of the University of Texas Mental Sciences Institute in Houston. He received the National Research Service Award for the
support of the postdoctoral fellowship. After this, he served a three-year residency in Psychiatry at the Department of Psychiatry
and Behavioral Sciences at the University of Texas Medical School at Houston as well as a two-year fellowship in Child and Adolescent
Psychiatry.
Dr. Jain is currently involved in multiple research projects studying the effects of medications on short-term and long-term treatment
of depression, anxiety, pain/mood overlap disorders, and psychosis in adult and child/adolescent populations. He is the
author of several articles on the issue of mood and pain conditions. He serves on several Boards focusing on drug development
and disease state education. He was recently named “Public Citizen of the Year” by the National Association of Social Workers, Gulf
Coast Chapter, in recognition of community and peer education and championing of mental health issues. He was also recently
awarded the “Extra Mile Award” by the local school district, in recognition of the service to the children of the school district and
consultation to the teachers and counselors.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE
activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or
devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has
evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant
information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bailey has disclosed that he receives research support from Ortho-McNeil, Inc. He is on the speakers bureaus of Eli Lilly and
Company, Bristol-Myers Squibb Company, and Ortho-McNeil, Inc., and serves as a consultant to Eli Lilly and Company and Bristol-
Myers Squibb Company.
Dr. Maletic has disclosed that he is on the speakers bureaus of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and
Takeda Pharmaceuticals North America, Inc., and that he serves as a consultant to Eli Lilly and Company and Pfizer Inc.
Dr. Trivedi has disclosed that he receives research support from Bristol-Myers Squibb Company, Cephalon, Inc., Corcept
Therapeutics, Inc., Cyberonics, Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., Merck & Co., Inc.,
National Alliance for Research on Schizophrenia and Depression, National Institute of Mental Health, Novartis Pharmaceuticals
Corporation, Pfizer Inc., Pharmacia & Upjohn, Inc., Predix Pharmaceuticals, Solvay Pharmaceuticals, Inc., and Wyeth-Ayerst. He
is on the advisory boards of and/or serves as a consultant to Abbott Laboratories, Akzo (Organon Pharmaceuticals USA Inc.),
AstraZeneca Pharmaceuticals LP, Bayer Corp., Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc., Eli Lilly and Company,
Fabre-Kramer Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., Johnson & Johnson Pharmaceutical
Research & Development, L.L.C., Mead Johnson, Neuronetics Inc., Park-Davis Pharmaceuticals, Inc., Pfizer Inc., Pharmacia & Upjohn,
Inc., Sepracor Inc., Solvay Pharmaceuticals, Inc., VantagePoint, and Wyeth-Ayerst. Dr. Trivedi is on the speakers bureaus of Abdi
IBrahim, Akzo (Organon Pharmaceuticals USA Inc.), Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc., Eli Lilly and
Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., Pharmacia & Upjohn, Inc., Solvay Pharmaceuticals, Inc., and
Wyeth-Ayerst.
Dr. Jain has disclosed that he receives research support from Forest Laboratories, Inc., Eli Lilly and Company, Pfizer Inc., and
Wyeth Pharmaceuticals. He is on the speakers bureaus of Forest Laboratories, Inc., Eli Lilly and Company, Pfizer Inc., and Takeda
Pharmaceuticals North America, Inc. Dr, Jain serves as a consultant to Forest Laboratories, Inc., Eli Lilly and Company, Pfizer
Inc., and Takeda Pharmaceuticals North America, Inc. He also receives support for CME program development from Forest
Laboratories, Inc., Eli Lilly and Company and Pfizer Inc.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The
faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational
uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, Quadrant Medical Education, the faculty, and Eli Lilly and Company and Wyeth Pharmaceuticals do not
endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures,
products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or
dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WC-005-092208-90
